SLI
ALXN

Sumitomo Life Insurance’s Alexion Pharmaceuticals ALXN Stock Holding History

Sumitomo Life Insurance’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,268
Closed -$1.12M – 292
2017
Q1 		$1.12M Sell
9,268
-575
-6% -$74.1K 0.16% 203
2016
Q4 		$1.2M Buy
9,843
+219
+2% +$26.8K 0.17% 196
2016
Q3 		$1.18M Sell
9,624
-1,167
-11% -$150K 0.17% 194
2016
Q2 		$1.26M Sell
10,791
-366
-3% -$51.9K 0.17% 199
2016
Q1 		$1.55M Buy
11,157
+3,358
+43% +$493K 0.2% 164
2015
Q4 		$1.49M Sell
7,799
-184
-2% -$32.1K 0.19% 178
2015
Q3 		$1.25M Sell
7,983
-202
-2% -$36.8K 0.17% 207
2015
Q2 		$1.48M Sell
8,185
-1,014
-11% -$175K 0.18% 202
2015
Q1 		$1.59M Sell
9,199
-974
-10% -$176K 0.18% 201
2014
Q4 		$1.88M Sell
10,173
-579
-5% -$107K 0.19% 197
2014
Q3 		$1.78M Buy
10,752
+2,874
+36% +$472K 0.17% 212
2014
Q2 		$1.23M Buy
+7,878
New +$1.24M 0.12% 249

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Sumitomo Life Insurance's ALXN Position: Q2 2017 in Review

Sumitomo Life Insurance sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 9,268 shares — an estimated $1.12M sold.

Sumitomo Life Insurance first reported a position in ALXN in Q2 2014 and held it in 12 quarters. The position peaked at $1.88M in Q4 2014. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Sumitomo Life Insurance reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Sumitomo Life Insurance sold 9,268 Alexion Pharmaceuticals shares in Q2 2017, an estimated $1.12M.
  • Sumitomo Life Insurance first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 12 quarters.
  • Sumitomo Life Insurance's Alexion Pharmaceuticals position peaked at $1.88M in Q4 2014.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Sumitomo Life Insurance's 13F filing for Q2 2017, filed 27 Jul 2017.